Autopsy report · NCT05057689

Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room

“Unable to obtain funding to initiate/complete study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Nationwide Children's Hospital

Sponsor type

University, hospital or other

Conditions

Acute Stress Disorder; Anxiety; Pain

Interventions

Intranasal Dexmedetomidine (4 mcg/kg); Intranasal Fentanyl (2 mcg/kg); Intranasal Midazolam (5 mg/kg)

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment
  “Could not obtain approval for the planned study with available funding” (87% match in meaning)
• Complementary/Integrative Medicine for Brain Cancer Patients
  “Unable to attain funding” (86% match in meaning)
• Study of EQU-001 for Uncontrolled Focal Onset Seizures
  “insufficient funding to complete the study” (86% match in meaning)
• L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder
  “Study funding has not been established” (84% match in meaning)
• Hemp-Derived Botanical Dietary Supplementation During Recovery From Brain Injury
  “Lack of initial funding after approval of study” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.